# Atrial Fibrillation Risk: GLP-1 vs SGLT-2 vs DPP-4 Inhibitors | This GLP A network meta-analysis of 2,171,267 patients found GLP-1 drugs no different from DPP-4 inhibitors on atrial fibrillation (RR 0.93), with SGLT-2 inhibitors ahead of both. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/atrial-fibrillation-the-other-drug-won Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Atrial Fibrillation Risk: GLP-1 vs SGLT-2 vs DPP-4 Inhibitors Across 2,171,267 patients, GLP-1 drugs showed no detectable advantage over DPP-4 inhibitors on atrial fibrillation. SGLT-2 inhibitors beat both, and nothing helped recurrence. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Atrial fibrillation risk · 1.0 · SGLT-2i vs GLP-1 · SGLT-2i vs DPP-4i · GLP-1 vs DPP-4i · The bottom row is the one about these drugs. It crosses the line. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A network meta-analysis of 4 randomized trials and 21 cohort studies, 2,171,267 patients, compared three diabetes drug classes on atrial fibrillation risk. - GLP-1 drugs were not significantly different from DPP-4 inhibitors, at a risk ratio of 0.93 (95% CI 0.84-1.03). - SGLT-2 inhibitors beat both — 0.86 (95% CI 0.79-0.95) against GLP-1 drugs and 0.80 (95% CI 0.74-0.87) against DPP-4 inhibitors. - For recurrence of atrial fibrillation in people who already have it, no class separated from any other. These drugs accumulate favorable cardiovascular findings steadily enough that it is worth marking where they do not. On atrial fibrillation, a network meta-analysis covering 2,171,267 patients across three drug classes puts them second [\[1\]](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won#ref-1). The heart failure picture, where the evidence runs the other way, is in [the heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure). Against DPP-4 inhibitors — the standard near-neutral comparator in diabetes research — GLP-1 drugs showed a risk ratio of 0.93 with a confidence interval of 0.84 to 1.03. That interval crosses 1, so the honest summary is no detectable difference. New-onset atrial fibrillation gave the same answer, at 0.93 (95% CI 0.83–1.04). SGLT-2 inhibitors separated from both. They beat GLP-1 drugs at 0.86 (95% CI 0.79–0.95) and DPP-4 inhibitors at 0.80 (95% CI 0.74–0.87), consistently across sensitivity analyses. For anyone whose main concern is atrial fibrillation specifically, this evidence points at a different drug class. For people who already have it, nothing separated Recurrence of atrial fibrillation showed no significant difference between any of the three classes, with every interval crossing 1. The question these comparisons answer is about developing the condition, not about managing it once present. The evidence grade deserves attention before the headcount does. Four randomized trials and 21 cohort studies means the bulk of that two million is observational, and a network meta-analysis compares treatments indirectly where trials did not test them against each other. Large numbers of observational patients do not substitute for randomization, and the confidence intervals here reflect statistical precision rather than freedom from bias — the same distinction that governs [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute). None of this argues against taking a GLP-1 drug. It argues against a particular kind of reasoning, in which a drug with real cardiovascular benefits is assumed to have every cardiovascular benefit. The benefits that do hold up are specific, and so are the absences, which is the same pattern visible in [the rheumatoid arthritis cohort](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis) where one component of a composite moved and three did not, and in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). ## Frequently asked Do GLP-1 drugs reduce atrial fibrillation risk? Not detectably in this analysis. Against DPP-4 inhibitors the risk ratio was 0.93 with an interval from 0.84 to 1.03, which crosses no difference. Which class did best? SGLT-2 inhibitors, which were associated with lower atrial fibrillation risk than both GLP-1 drugs (0.86) and DPP-4 inhibitors (0.80). What if I already have atrial fibrillation? Nothing here distinguishes the three classes on recurrence. Every comparison for recurrence had an interval crossing no difference. ## Sources 1. \[1\] Ye X, Wu Q, Hou L, Hou X, Yang Y, Yang C, Huang M, Wang S (2026). Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus Diabetes/Metabolism Research and Reviews. [PMID 42455922](https://pubmed.ncbi.nlm.nih.gov/42455922/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)